(ONTO) Onto Innovation - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US6833441057
Stock:
Total Rating 56
Risk 85
Buy Signal 0.32
| Risk 5d forecast | |
|---|---|
| Volatility | 57.0% |
| Relative Tail Risk | -8.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.87 |
| Alpha | 6.26 |
| Character TTM | |
|---|---|
| Beta | 2.340 |
| Beta Downside | 2.087 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.82% |
| CAGR/Max DD | 0.58 |
EPS (Earnings per Share)
Revenue
Description: ONTO Onto Innovation
Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology and inspection worldwide. The company offers lithography systems and process control analytical software. It also provides process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements. In addition, the company offers process control software portfolio that includes solutions for standalone tools, groups of tools, and enterprise-or factory-wide suites. Further, it engages in systems and software, spare parts, and other services, as well as offers software licensing services. The company's products are used in semiconductor and advanced packaging device manufacturers; silicon wafers; light emitting diodes; vertical-cavity surface-emitting lasers; micro-electromechanical systems; CMOS image sensors; power devices; analog devices; RF filters; data storage; and various industrial and scientific applications. Onto Innovation Inc. was founded in 1940 and is headquartered in Wilmington, Massachusetts.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 136.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.56 > 1.0 |
| NWC/Revenue: 104.4% < 20% (prev 132.4%; Δ -28.06% < -1%) |
| CFO/TA 0.14 > 3% & CFO 328.3m > Net Income 136.8m |
| Net Debt (-625.6m) to EBITDA (220.4m): -2.84 < 3 |
| Current Ratio: 5.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.5m) vs 12m ago -0.18% < -2% |
| Gross Margin: 49.72% > 18% (prev 0.52%; Δ 4919 % > 0.5%) |
| Asset Turnover: 44.83% > 50% (prev 46.64%; Δ -1.81% > 0%) |
| Interest Coverage Ratio: -15.63 > 6 (EBITDA TTM 220.4m / Interest Expense TTM -9.79m) |
Altman Z'' 10.00
| A: 0.44 (Total Current Assets 1.27b - Total Current Liabilities 218.9m) / Total Assets 2.37b |
| B: 0.31 (Retained Earnings 733.3m / Total Assets 2.37b) |
| C: 0.07 (EBIT TTM 153.1m / Avg Total Assets 2.24b) |
| D: 7.86 (Book Value of Equity 2.10b / Total Liabilities 267.1m) |
| Altman-Z'' Score: 12.63 = AAA |
Beneish M -2.73
| DSRI: 0.86 (Receivables 268.9m/308.1m, Revenue 1.01b/987.3m) |
| GMI: 1.05 (GM 49.72% / 52.19%) |
| AQI: 1.73 (AQ_t 0.41 / AQ_t-1 0.24) |
| SGI: 1.02 (Revenue 1.01b / 987.3m) |
| TATA: -0.08 (NI 136.8m - CFO 328.3m) / TA 2.37b) |
| Beneish M-Score: -2.73 (Cap -4..+1) = A |
What is the price of ONTO shares?
As of March 01, 2026, the stock is trading at USD 215.89 with a total of 755,962 shares traded.
Over the past week, the price has changed by -0.24%, over one month by +3.56%, over three months by +50.80% and over the past year by +48.31%.
Over the past week, the price has changed by -0.24%, over one month by +3.56%, over three months by +50.80% and over the past year by +48.31%.
Is ONTO a buy, sell or hold?
Onto Innovation has received a consensus analysts rating of 4.11.
Therefore, it is recommended to buy ONTO.
- StrongBuy: 4
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ONTO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 265.7 | 23.1% |
| Analysts Target Price | 265.7 | 23.1% |
ONTO Fundamental Data Overview February 28, 2026
P/E Trailing = 61.3747
P/E Forward = 22.8311
P/S = 10.7617
P/B = 3.4902
P/EG = 0.7604
Revenue TTM = 1.01b USD
EBIT TTM = 153.1m USD
EBITDA TTM = 220.4m USD
Long Term Debt = unknown (none)
Short Term Debt = 5.62m USD (from shortTermDebt, two quarters ago)
Debt = 14.1m USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -625.6m USD (calculated as Total Debt 14.1m - CCE 639.6m)
Enterprise Value = 10.19b USD (10.82b + Debt 14.1m - CCE 639.6m)
Interest Coverage Ratio = -15.63 (Ebit TTM 153.1m / Interest Expense TTM -9.79m)
EV/FCF = 34.00x (Enterprise Value 10.19b / FCF TTM 299.8m)
FCF Yield = 2.94% (FCF TTM 299.8m / Enterprise Value 10.19b)
FCF Margin = 29.82% (FCF TTM 299.8m / Revenue TTM 1.01b)
Net Margin = 13.60% (Net Income TTM 136.8m / Revenue TTM 1.01b)
Gross Margin = 49.72% ((Revenue TTM 1.01b - Cost of Revenue TTM 505.5m) / Revenue TTM)
Gross Margin QoQ = 46.39% (prev 50.70%)
Tobins Q-Ratio = 4.30 (Enterprise Value 10.19b / Total Assets 2.37b)
Interest Expense / Debt = 22.51% (Interest Expense 3.17m / Debt 14.1m)
Taxrate = 46.07% (9.00m / 19.5m)
NOPAT = 82.6m (EBIT 153.1m * (1 - 46.07%))
Current Ratio = 5.79 (Total Current Assets 1.27b / Total Current Liabilities 218.9m)
Debt / Equity = 0.01 (Debt 14.1m / totalStockholderEquity, last quarter 2.10b)
Debt / EBITDA = -2.84 (Net Debt -625.6m / EBITDA 220.4m)
Debt / FCF = -2.09 (Net Debt -625.6m / FCF TTM 299.8m)
Total Stockholder Equity = 2.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.10% (Net Income 136.8m / Total Assets 2.37b)
RoE = 6.85% (Net Income TTM 136.8m / Total Stockholder Equity 2.00b)
RoCE = 7.13% (EBIT 153.1m / Capital Employed (Total Assets 2.37b - Current Liab 218.9m))
RoIC = 4.21% (NOPAT 82.6m / Invested Capital 1.96b)
WACC = 14.54% (E(10.82b)/V(10.83b) * Re(14.54%) + D(14.1m)/V(10.83b) * Rd(22.51%) * (1-Tc(0.46)))
Discount Rate = 14.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.02%
[DCF] Terminal Value 62.89% ; FCFF base≈265.4m ; Y1≈327.4m ; Y5≈557.5m
[DCF] Fair Price = 92.69 (EV 3.98b - Net Debt -625.6m = Equity 4.60b / Shares 49.7m; r=14.54% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 3.81 | EPS CAGR: -1.03% | SUE: 0.0 | # QB: 0
Revenue Correlation: 24.14 | Revenue CAGR: 2.72% | SUE: -0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.32 | Chg7d=+0.066 | Chg30d=+0.050 | Revisions Net=+5 | Analysts=7
EPS current Year (2026-12-31): EPS=6.52 | Chg7d=+0.289 | Chg30d=+0.327 | Revisions Net=+7 | Growth EPS=+31.9% | Growth Revenue=+24.9%
EPS next Year (2027-12-31): EPS=8.18 | Chg7d=+0.497 | Chg30d=+0.497 | Revisions Net=+5 | Growth EPS=+25.5% | Growth Revenue=+15.6%
[Analyst] Revisions Ratio: +0.71 (6 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 12.9% (Discount Rate 14.5% - Earnings Yield 1.6%)
[Growth] Growth Spread = -7.8% (Analyst 5.1% - Implied 12.9%)
P/E Forward = 22.8311
P/S = 10.7617
P/B = 3.4902
P/EG = 0.7604
Revenue TTM = 1.01b USD
EBIT TTM = 153.1m USD
EBITDA TTM = 220.4m USD
Long Term Debt = unknown (none)
Short Term Debt = 5.62m USD (from shortTermDebt, two quarters ago)
Debt = 14.1m USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -625.6m USD (calculated as Total Debt 14.1m - CCE 639.6m)
Enterprise Value = 10.19b USD (10.82b + Debt 14.1m - CCE 639.6m)
Interest Coverage Ratio = -15.63 (Ebit TTM 153.1m / Interest Expense TTM -9.79m)
EV/FCF = 34.00x (Enterprise Value 10.19b / FCF TTM 299.8m)
FCF Yield = 2.94% (FCF TTM 299.8m / Enterprise Value 10.19b)
FCF Margin = 29.82% (FCF TTM 299.8m / Revenue TTM 1.01b)
Net Margin = 13.60% (Net Income TTM 136.8m / Revenue TTM 1.01b)
Gross Margin = 49.72% ((Revenue TTM 1.01b - Cost of Revenue TTM 505.5m) / Revenue TTM)
Gross Margin QoQ = 46.39% (prev 50.70%)
Tobins Q-Ratio = 4.30 (Enterprise Value 10.19b / Total Assets 2.37b)
Interest Expense / Debt = 22.51% (Interest Expense 3.17m / Debt 14.1m)
Taxrate = 46.07% (9.00m / 19.5m)
NOPAT = 82.6m (EBIT 153.1m * (1 - 46.07%))
Current Ratio = 5.79 (Total Current Assets 1.27b / Total Current Liabilities 218.9m)
Debt / Equity = 0.01 (Debt 14.1m / totalStockholderEquity, last quarter 2.10b)
Debt / EBITDA = -2.84 (Net Debt -625.6m / EBITDA 220.4m)
Debt / FCF = -2.09 (Net Debt -625.6m / FCF TTM 299.8m)
Total Stockholder Equity = 2.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.10% (Net Income 136.8m / Total Assets 2.37b)
RoE = 6.85% (Net Income TTM 136.8m / Total Stockholder Equity 2.00b)
RoCE = 7.13% (EBIT 153.1m / Capital Employed (Total Assets 2.37b - Current Liab 218.9m))
RoIC = 4.21% (NOPAT 82.6m / Invested Capital 1.96b)
WACC = 14.54% (E(10.82b)/V(10.83b) * Re(14.54%) + D(14.1m)/V(10.83b) * Rd(22.51%) * (1-Tc(0.46)))
Discount Rate = 14.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.02%
[DCF] Terminal Value 62.89% ; FCFF base≈265.4m ; Y1≈327.4m ; Y5≈557.5m
[DCF] Fair Price = 92.69 (EV 3.98b - Net Debt -625.6m = Equity 4.60b / Shares 49.7m; r=14.54% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 3.81 | EPS CAGR: -1.03% | SUE: 0.0 | # QB: 0
Revenue Correlation: 24.14 | Revenue CAGR: 2.72% | SUE: -0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.32 | Chg7d=+0.066 | Chg30d=+0.050 | Revisions Net=+5 | Analysts=7
EPS current Year (2026-12-31): EPS=6.52 | Chg7d=+0.289 | Chg30d=+0.327 | Revisions Net=+7 | Growth EPS=+31.9% | Growth Revenue=+24.9%
EPS next Year (2027-12-31): EPS=8.18 | Chg7d=+0.497 | Chg30d=+0.497 | Revisions Net=+5 | Growth EPS=+25.5% | Growth Revenue=+15.6%
[Analyst] Revisions Ratio: +0.71 (6 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 12.9% (Discount Rate 14.5% - Earnings Yield 1.6%)
[Growth] Growth Spread = -7.8% (Analyst 5.1% - Implied 12.9%)